feed,title,long_url,short_url
Benzinga,"AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication",https://benzinga.com/general/biotech/22/09/28717066/anaptysbio-faces-another-setback-for-imsidolimab-stalls-work-in-skin-scarring-indication,https://bit.ly/3CPMd9l
Benzinga,"After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal",https://benzinga.com/general/biotech/22/09/28716575/after-pfizer-now-novo-nordisk-beefs-up-its-sickle-cell-portfolio-with-forma-therapeutics-deal,https://bit.ly/3R6CxeQ
